Cystinosis Results Help Rebuild Confidence In AvroBio’s Gene Therapy
Potential Registrational Study To Start This Year
Executive Summary
The lentiviral gene therapy company is still trading below cash, but the cystinosis results add extra momentum to its comeback.
You may also be interested in...
Avrobio Plots Comeback With Early Data From Gaucher’s Gene Therapy
Early data in Gaucher disease suggest Avrobio’s hematopoietic stem cell gene therapy could help patients who do not response to enzyme replacement therapy.
Avrobio Plots Plan B After Fabry Disease Gene Therapy Problems
Avrobio is sidestepping market and regulatory issues in Fabry disease by suspending development of AVR-RD-01, but says it remains focused on advancing treatment of lysosomal storage disorders with gene therapies.
Antibody-Drug Conjugates Take Their Place On The ASCO 2023 Stage
Investment from big and small players against existing and novel targets is making antibody-drug conjugates one of the fastest-growing fields in oncology, as attested by their presence at the upcoming ASCO meeting.